cetpinhibition.org

HDL biology

Psyllium plus plant sterols lowers CETP activity by 11% and raises LDL receptor abundance by 26%, explaining part of its LDL-lowering mechanism (J Nutr 2007)

Original title: A combination of psyllium and plant sterols alters lipoprotein metabolism in hypercholesterolemic subjects by modifying the intravascular processing of lipoproteins and increasing LDL uptake

J Nutr · · 5

Shrestha S, Freake HC, McGrane MM, Volek JS, Fernandez ML

Building on prior findings that psyllium plus plant sterols (PSY+PS) lowers LDL cholesterol in 33 hypercholesterolemic subjects in a randomized, double-blind crossover trial, this study examined the intravascular and molecular mechanisms. PSY+PS intake decreased cholesterol in LDL-1 (2.46 +/- 0.66 to 2.26 +/- 0.46 mmol/L) and LDL-2 (0.63 +/- 0.24 to 0.54 +/- 0.27 mmol/L, P < 0.05 for both), increased LDL peak size (27.3 +/- 0.8 to 27.5 +/- 0.6 nm, P < 0.05), and decreased the prevalence of atherogenic LDL pattern B from 27% to 18% (P < 0.05). Cholesteryl ester transfer protein activity was 11% lower during the test period (P < 0.05), and LDL receptor abundance in circulating mononuclear cells was 26% higher (P < 0.03), indicating the hypocholesterolemic action of PSY+PS involves both altered intravascular lipoprotein processing and increased LDL receptor-mediated uptake.

Read the paper (DOI)PubMed

Original abstract

We previously demonstrated that a diet therapy involving consumption of 7.28 g psyllium (PSY) and 2 g of plant sterols (PS) per day reduced LDL cholesterol from 3.6 +/- 0.7 to 3.1 +/- 0.8 mmol/L (P < 0.01) and decreased the number of intermediate density lipoprotein particles and the smaller LDL and HDL subfractions in hypercholesterolemic individuals (n = 33). The study design was a randomized double blind crossover. Subjects consumed either 2 test cookies containing PSY+PS or 2 placebo cookies for 1 mo with a 3-wk wash out between treatments. To explore mechanisms of the lipid-lowering effects of combined PSY+PS, we present data related to intravascular and molecular regulation. Intake of PSY+PS decreased the cholesterol concentration in LDL-1 from 2.46 +/- 0.66 to 2.26 +/- 0.46 mmol/L and in LDL-2 from 0.63 +/- 0.24 to 0.54 +/- 0.27 mmol/L (P < 0.05) in the test compared with the placebo period. An increase in LDL peak size from 27.3 +/- 0.8 to 27.5 +/- 0.6 nm (P < 0.05) and a decrease in the prevalence of LDL pattern B from 27 to 18% (P < 0.05) also occurred during the PSY+PS period. Cholesteryl ester transfer protein activity was 11% lower (P < 0.05) during the test period. Notably, the abundance of the LDL receptor in circulating mononuclear cells as measured by real time PCR was 26% higher during the test compared with the placebo period (P < 0.03). These results indicate that the hypocholesterolemic action of PSY and PS can be explained in part by modifications in the intravascular processing of lipoproteins and by increases in LDL receptor-mediated uptake.

HDL biology

Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.